Donate
Return to Map
Return to Map

Kentucky Bladder Cancer Resources

Kentucky Cabinet for Health and Family Services -- Department for Public Health
http://chfs.ky.gov/agencies/dph/Pages/default.aspx

Contact Your State Elected Representative

Bladder Cancer Cases in Kentucky at a Glance

  • 1,240

    New State Cases
     

  • 83,190

    New National
    Cases

  • 63,070

    National Cases in Men

  • 20,120

    National Cases in Women

  • 16,840

    National Deaths
     

NCI-Designated Cancer Centers and NCCN Member Institutions

The National Cancer Institute, (NCI) has recognized Cancer Centers for delivering cutting-edge cancer treatments to patients in communities across the United States. There are 71 NCI-Designated Cancer Centers, located in 36 states and the District of Columbia, that are funded by NCI to deliver cutting-edge cancer treatments to patients. Most of the NCI-Designated Cancer Centers are affiliated with university medical centers, although several are freestanding institutions that engage only in cancer research.

The National Comprehensive Cancer Centers (NCCN) are a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.

Markey Cancer Center

Lexington, KY
859-257-4500

Veterans Administration Hospitals

Cincinnati VA Medical Center -- Fort Thomas
Lexington VA Health Care System
Lexington VAMC: Cooper Divisiion
Lexington VAMC: Leestown Division
Robley Rex VA Medical Center

Bladder Cancer Clinical Trials in Kentucky

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin Intravesical BCG vs GEMDOCE in NMIBC A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
See more clinical trials

Read Our Stories